chr21-45511090-T-TACAC
Variant summary
Our verdict is Uncertain significance. The variant received 0 ACMG points: 0P and 0B.
The NM_001379500.1(COL18A1):c.3694-18_3694-15dupACAC variant causes a intron change involving the alteration of a non-conserved nucleotide. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Consequence
NM_001379500.1 intron
Scores
Clinical Significance
Conservation
Publications
- combined immunodeficiencyInheritance: AR Classification: MODERATE Submitted by: PanelApp Australia
- immunodeficiency 114, folate-responsiveInheritance: AR Classification: LIMITED Submitted by: ClinGen
- megaloblastic anemia, folate-responsiveInheritance: AR Classification: LIMITED Submitted by: PanelApp Australia
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 0 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_001379500.1. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| COL18A1 | MANE Select | c.3694-21_3694-20insACAC | intron | N/A | ENSP00000498485.1 | P39060-2 | |||
| COL18A1 | TSL:1 | c.4234-21_4234-20insACAC | intron | N/A | ENSP00000347665.5 | P39060-1 | |||
| SLC19A1 | TSL:1 | c.1294-12479_1294-12478insGTGT | intron | N/A | ENSP00000457278.1 | H3BTQ3 |
Frequencies
GnomAD3 genomes Cov.: 0
GnomAD2 exomes AF: 0.00000655 AC: 1AN: 152704 AF XY: 0.0000123 show subpopulations
GnomAD4 exome AF: 9.62e-7 AC: 1AN: 1039534Hom.: 0 Cov.: 18 AF XY: 0.00000190 AC XY: 1AN XY: 526112 show subpopulations
GnomAD4 genome Cov.: 0
ClinVar
Not reported inComputational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.